Sorted By:

Relevance


New Report: Past Drug Failures Help Create the War on Cancer’s Next Successes

PhRMA  |  Press Release

View the full “Researching Cancer Medicines: Setbacks and Stepping Stones” report
https://www.phrma.org/press-release/new-report-past-drug-failures-help-create-the-war-on-cancer-s-next-successes

New PhRMA Report: Nearly 200 medicines in development for heart disease, stroke and other cardiovascular diseases

PhRMA  |  Blog Post

View the full report here: Medicines in Development for Cardiovascular Diseases View the medicine list here: Heart Disease, Stroke Drug List
http://catalyst.phrma.org/new-phrma-report-medicines-in-development-for-heart-disease-stroke-2015

Medicines in Development for Older Americans 2013 Report

PhRMA  |  Report

These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 110 for diabetes, 62 for rheumatoid arthritis and osteoarthritis, 67 for Alzheimer’s disease, 61 for heart disease and 40 for chronic obstructive pulmonary disease (COPD), according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
https://www.phrma.org

New PwC report finds medicine spending still small share of health spending, concerns may trigger ‘false alarms’

PhRMA  |  Blog Post

” This is yet another report showing how the competitive biopharmaceutical market works to control costs and deliver new innovative treatments and cures patients desperately need.
http://catalyst.phrma.org/new-pwc-report-finds-medicine-spending-still-small-share-of-health-spending-concerns-may-trigger-false-alarms

Clinical Trials: Neurological Disorders

PhRMA  |  Report

There are more than 2,000 clinical trials listed in the National Institutes of Health database – www.clinicaltrials.gov – for neurological disorders, such as Alzheimer’s disease, brain tumors, chronic pain, epilepsy, headache, multiple sclerosis and Par...
https://www.phrma.org/report/clinical-trials-neurological-disorders

PhRMA Statement on Patent Reform

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.3 billion in 2009.
https://www.phrma.org/press-release/phrma-statement-on-patent-reform1

New Report Shows Over 3,200 Clinical Trials of Medicines Conducted by Indiana Research Institutions Since 1999

PhRMA  |  Press Release

The findings also show that research institutions in Indiana are conducting clinical trials of new medicines in collaboration with biopharmaceutical companies, including: Cancer Care Center Inc., New Albany Central Indiana Cancer Centers, Carmel, Fishers, Indianapolis Children’s Center for Cancer and Blood Diseases, Indianapolis Indiana University Hospital, Indianapolis Indiana University School of Medicine, Indianapolis Oncology Hematology Associates of Southwest Indiana, Evansville, Newburgh Lafayette Regional Vein and Laser Center, Lafayette Deaconess Hospital-The Heart Group, Evansville Premier Healthcare, Bloomington For a listing of all clinical trials recruiting patients and their locations in Indiana, consult the appendix of the “Research in Your Backyard” report, which can be found at http://www.phrma.org/innovation/research-in-your-backyard. 
https://www.phrma.org/press-release/new-report-shows-over-3-200-clinical-trials-of-medicines-conducted-by-indiana-research-institutions-since-1999

Chart Pack: Value of Personalized Medicine

PhRMA  |  Report

Data and information found in this publication were drawn from a wide range of sources,  including government agency reports, peer?
https://www.phrma.org/report/chart-pack-value-of-personalized-medicine

Let's Talk About Cost

PhRMA  |  From PhRMA

View reports that explore the slowdown in medicine cost growth, the rising cost of chronic disease, insurance coverage of medicine, the role of middlemen, and what our industry can do to make medicine more affordable for patients.
https://www.phrma.org/media/let-s-talk-about-cost

Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2006-2015

PhRMA  |  Report

Research on the pricing of prescription drugs tends to focus on individual products, rather than the overall pricing trend for the market as a whole. This larger trend—which is influenced by multiple competitive forces, including competition among products in therapeutic classes and entry o...
https://www.phrma.org/report/trends-in-weighted-average-sales-prices-for-prescription-drugs-in-medicare-part-b-2006-2015

An Analysis of Exchange Plan Benefits for Certain Medicines

Access Better Coverage  |  From Our Network

Additional oversight and stronger standards for formulary design would help prevent the practices described in this report.
http://www.accessbettercoverage.org/reports/an-analysis-of-exchange-plan-benefits-for-certain-medicines

STEM

PhRMA  |  Report

Continued scientific and technological innovations are critical to fostering sustained economic growth, global competitiveness, and most importantly, helping patients live longer, healthier, and more productive lives. The U.S. innovative biopharmaceutical industry is committed to building on new ...
https://www.phrma.org/report/stem

New Report: Nearly 4.5 Million U.S. Jobs and $1.2 Trillion Economic Output Supported by Biopharmaceutical Sector in 2014

PhRMA  |  Press Release

A U.S. fact sheet and fact sheets for all 50 states plus the District of Columbia are available online, as is the full report with detailed findings and methodology.
https://www.phrma.org/press-release/new-report-nearly-4-5-million-u-s-jobs-and-1-2-trillion-economic-output-supported-by-biopharmaceutical-sector-in-2014

Commercially-Insured Patients Pay Undiscounted List Prices for One In Five Brand Prescriptions, Accounting for Half of Out-of-Pocket Spending on Brand Medicines

PhRMA  |  Report

Patients with deductibles and coinsurance for prescription medicines pay cost-sharing that is based on the undiscounted list price of a medicine, rather than the discounted price negotiated by their health plan or pharmacy benefit manager (PBM). In the commercial market, one in five prescriptions...
https://www.phrma.org/report/commercially-insured-patients-pay-undiscounted-list-prices-for-one-in-five-brand-prescriptions-accounting-for-half-of-out-of-pocket-spending-brand-medicines

PhRMA Statement on Health Care Reform

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/phrma-statement-on-health-care-reform1

New Drug Approvals in 2011

PhRMA  |  Report

America’s biopharmaceutical research companies obtained approval for 35 new medicines in 2011 from the U.S. Food and Drug Administration (FDA). The medicines include 24 new drugs (also called new molecular entities or NMEs), six therapeutic biologics, and five other biologics. Eleven of the new m...
https://www.phrma.org/report/new-drug-approvals-in-2011

Clinical Trials: Blood Cancers

PhRMA  |  Report

There are 1,679 clinical trials listed in the National Institutes of Health database --www.clinicaltrials.gov -- for blood cancers.  Of those trials, 484 are either recruiting patients or have not yet started recruiting patients. This information is pot...
https://www.phrma.org/report/clinical-trials-blood-cancers

Policy Solutions: Engaging and Empowering Consumers

PhRMA  |  Report

Informed, engaged consumers are well equipped to judge the value of their health care. And yet, consumers too often are frustrated by hurdles that make it hard to access information about their insurance benefits and out-of-pocket health care costs. By removing some of these hurdles, we can help ...
https://www.phrma.org/report/engaging-and-empowering-consumers

New Report Shows Major Diseases Being Addressed With Over 230 Medicines in Development for Children

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/new-report-shows-major-diseases-being-addressed-with-over-230-medicines-in-development-for-children

UK Cancer Patients Face Increasing Coverage Restrictions Due to Centralized Cost-Effectiveness Standard, New Report Shows

PhRMA  |  Press Release

Washington, D.C. (July 10, 2014)  – New research results announced today quantify the extent to which centralized value assessments by the UK’s National Institute for Health and Care Excellence ...
https://www.phrma.org/press-release/uk-cancer-patients-face-increasing-coverage-restrictions-due-to-centralized-cost-effectiveness-standard-new-report-shows

Modernizing Drug Discovery, Development & Approval

PhRMA  |  Report

Developing an innovative medicine is a lengthy and complex process, taking an average of 10 or more years. The clinical trial component alone takes roughly six to seven years. With just 12 percent of drugs that enter clinical trials resulting in an approved medicine, the average research and deve...
https://www.phrma.org/report/policy-solutions-modernizing-drug-discovery-development-and-approval

An Analysis of Exchange Plan Benefits for Certain Medicines

PhRMA  |  Report

A new report demonstrates that the majority of plans in the Health Insurance Exchanges are placing a significant out-of-pocket burden on patients with serious illnesses by requiring particularly high cost-sharing for all medicines used to treat certain conditions. 
https://www.phrma.org/report/an-analysis-of-exchange-plan-benefits-for-certain-medicines

Significant progress fighting cancer: Death rate has dropped 25 percent

PhRMA  |  Blog Post

Researchers continue to better understand the disease’s complexities, and today, there are more than 800 medicines and vaccines in clinical testing for cancer – approximately 80 percent of which are potentially the first of their kind.
http://catalyst.phrma.org/significant-progress-fighting-cancer-death-rate-has-dropped-25

New Report: Many Exchange Plans Burden the Most Vulnerable Patients with High Out-of-Pocket Costs for Vital Medicines; Patients left with limited access

PhRMA  |  Press Release

  The full report is available here.
https://www.phrma.org/press-release/new-report-many-exchange-plans-burden-the-most-vulnerable-patients-with-high-out-of-pocket-costs-for-vital-medicines-patients-left-with-limited-access

HIV Aids In this Together

PhRMA  |  Report

HIV/AIDS was once a death sentence. Today, it can be a manageable chronic disease. By working together, we can continue the progress toward a cure. This week, at the 2014 Research and Hope Awards, we are coming together to recognize those who have helped lead the fight against HIV/AIDS....
https://www.phrma.org/report/hiv-aids-in-this-together

You have reviewed the first 225 results out of 1029. Each page contains 25 results. You're on page 9.

prev 7 8 9 10 11 12 next